Contributing Member of the Healthcare Councils

GLG News by this Author

Bausch & Lomb's FDA Approved Topical Eye Antibiotic Besivance (Besifloxacin) Will Become Game Changer

June 15, 2009

Analysis of:Bausch and Lomb (BOL) Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') | www.lifescience-online.com

This novel and potent fluoroquinolone designed exclusively for ophthalmic use will gain significant market share of the ocular antibiotics prescribed in the US at the expense of Vigamox (Alcon) and Zymar (Allergan), the current leaders.  This will happen because cataract surgeons and contact lens specialists are concerned about the rising incidence of antibiotic resistance and MRSA (methicillin-resistant staph. aureus) infections.  When it comes to eye infections (endophthalmitis, bacterial corneal ulcers), there is no margin for error and clinicians will always prescribe the most potent ophthalmic antibiotic available regardless of its cost and insurance formulary coverage.

New Glaucoma Product Should Simplify Patient Compliance and Increase Allergan's Share of Glaucoma Market

November 6, 2007

Analysis of:Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com

Patient compliance with glaucoma eyedrops is a key barrier in achieveing acceptable clinical outcomes. There is only one other product, Cosopt (by Merck) that offers a combination glaucoma medication. This medication may become a popular choice for glaucoma doctors to improve patient compliance.

Page : 11 to 2 of 2